A Gut Reaction

by Takeda UK and Ireland/Oxford University Hospital with support from IQVIA

Summary of work

When Takeda identified that UK moderate-to-severe inflammatory bowel disease (IBD) patients were not able to receive treatment in a timely manner, a solution was needed. Infusion capacity at the John Radcliffe Hospital was causing patients with active disease to wait, on average, nine to ten weeks to receive biologic treatment.

To address this issue, Takeda collaborated with Oxford University Hospitals NHS Foundation Trust (OUHFT) and IQVIA to explore new service models to address the capacity issues delivering a better patient experience. The output of group problem-solving sessions was to create a community infusion clinic. The partnership added Oxford Health to take the additional steps needed to make the clinic a reality.

Takeda executed a Medical and Educational Goods and Services Grant, which funded IQVIA project management leadership. IQVIA used geo-mapping and stakeholder surveys to identify the optimal location for the infusion clinic and drove business case development/approval and operational clinic set-up activities.

An IBD community-based infusion service was successfully launched at Didcot Community Hospital on 5th June 2019. Now, a decision to treat IBD more aggressively is being met with timely intervention, which should help to improve patient outcomes, patient experience and reduce treatment burden in the Oxford region.

Judges’ comments

A Gut Reaction had strong measurements and outcomes. It built Takeda and Oxford University Hospital’s local trust and reputation with an in-depth understanding of the issues it covered.